Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment

Area of Science:

• Oncology
• Nanotechnology
• Immunotherapy

Background:

• Immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 improve survival in some advanced non-small cell lung cancer (NSCLC) patients.
• Limited response rates to current ICIs necessitate the development of superior immunotherapies for NSCLC.

Purpose of the Study:

• To develop and evaluate a nanoparticle-based immunotherapy, ARAC (Antigen Release Agent and Checkpoint Inhibitor), for enhanced PD-L1 inhibition in NSCLC.
• To investigate the synergistic potential of co-delivering a PLK1 inhibitor (volasertib) and a PD-L1 antibody via a nanoparticle platform.

Main Methods:

• ARAC nanoparticles were engineered to co-deliver volasertib (PLK1 inhibitor) and a PD-L1 antibody.
• Efficacy of ARAC was assessed in metastatic lung tumor models (LLC-JSP and KLN-205).
• The role of CD8+ T cells in mediating ARAC's therapeutic effect was investigated.

Main Results:

• ARAC demonstrated a 5-fold dose reduction for both volasertib and PD-L1 antibody in a metastatic lung tumor model.
• The therapeutic effect of ARAC was primarily mediated by CD8+ T cells.
• ARAC showed significant efficacy in a lung tumor model (KLN-205) unresponsive to combined CTLA-4 and PD-1 inhibitors.

Conclusions:

• ARAC represents a rational combination strategy to augment existing cancer immunotherapies.
• The nanoparticle platform enables co-delivery of multiple therapeutic agents for enhanced efficacy.
• ARAC holds promise for improving treatment outcomes in NSCLC, including ICI-resistant cases.